This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
CME Activities
Visualizing Updates in Melanoma Management: Novel Combinations, Development, and Best Practices in Sequencing Therapy
This activity is designed to meet the educational needs of oncologists, nurse practitioners, oncology pharmacists, and physician assistants to ensure confidence in the management of advanced melanoma.
The ACTIVATE Initiative Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies
This activity is designed to meet the educational needs of both community based and academic oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician’s assistants to ensure confidence in the management of advanced melanoma.
An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies
This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician’s assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immuno-therapy approaches in advanced melanoma.
Updating Best Practices for Management of Advanced Melanoma – Considering Current and Emerging Anti-LAG3 Combinations in the Veterans Affairs Setting
This enduring program focuses on providing Veterans Affairs clinicians with updates in the management of advanced melanoma, including consideration of anti-LAG-3 antibodies. It also provides an overview of the latest trials considering anti-LAG-3 antibodies for the management of advanced melanoma, and updates on immunotherapy approaches in clinical practice.
